The Liver Meeting
The Liver Meeting
November 13, 2016
3 min watch
Save

VIDEO: History of NAFLD cirrhosis increases family members' risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

BOSTON — In this exclusive video from The Liver Meeting, Rohit Loomba, MD, MHSc, director of the NAFLD Research Center, UC San Diego Health, and professor of medicine at UC San Diego School of Medicine, discusses how a first-degree relative of a person with nonalcoholic fatty liver disease cirrhosis has 12 times increased risk for developing cirrhosis.

“These data provide evidence to develop a screening program for individuals who have family history of NAFLD cirrhosis in family members,” Loomba said.

Loomba and colleagues conducted a cross-section analysis of a cohort of patients with NAFLD cirrhosis and their first-degree relatives. A total of 26 probands with NAFLD cirrhosis were included along with 39 first-degree relatives. The prevalence of cirrhosis in the general population was measured using a twin study design where a randomly assigned twin without cirrhosis and their twin pair were assessed for cirrhosis risk.

The researchers found the prevalence of cirrhosis in first-degree relative of patients with cirrhosis was higher compared with the control population.

“We found the risk of advance fibrosis if your first-degree relative had NAFLD cirrhosis was 18%, relative to 1% or less in the general population,” Loomba said.

After adjusting for multiple factors, such as age, BMI and gender, the risk was 12.5 times higher. “This is substantial risk,” Loomba said.

Disclosures: Loomba reports financial relationships with Adheron, AGA, Alnylam, Arrowhead Research Inc., Celgene, Corgenix, Daiichi Sankyo, Deutrx Inc., Galmed Inc., Gilead Sciences, Immuron, Inanta, Janssen and Janssen Inc., Kinemed, Merck, Promedior, Tobira Inc. and Zafgen.